@article{article_415387, title={Clinical and Laboratory Results and Prognosis Patients with Scleroderma: A Single Center Experience}, journal={Osmangazi Tıp Dergisi}, volume={40}, pages={70–78}, year={2018}, DOI={10.20515/otd.415387}, author={Özden Yılmaz, Ebru and Üsküdar Cansu, Döndü and Korkmaz, Cengiz}, keywords={Skleroderma,prognoz,malignite}, abstract={<p class="MsoNormal" style="text-align:justify;text-indent:0cm;line-height:normal;"> <span lang="en-us" style="font-size:10pt;font-family:’Times New Roman’, serif;" xml:lang="en-us">Systemic scleroderma (SSc) is a rare connective tissue
disease accompanied by progressive fibrosis. Especially pulmonary, cardiac and
renal involvement is a major cause of morbidity and mortality in the disease
while skin involvement and Raynaud’s phenomenon (RP) can also decrease the
quality of life by increasing morbidity. In this study, our aim was to
determine the demographics, organ involvement and prognosis of our SSc patients
followed up in Rheumatology department and compare the data with the
literature. For this purpose, the data of 79 patients who were followed up in
our department were evaluated retrospectively. 74 (93.7%) of the 79 patients
were female, the mean age of the patients was 54.3 ± 12.7 (22-76) years and the
mean duration of disease was 7.29 ± 7.02 years. 71 (89.8%) had limited
cutaneous SSc (lcSSc), 6 (7.6%) had diffuse cutaneous SSc (dcSSc) and 2 (2.5%)
had sine scleroderma. When the cumulative organ involvement of the patients was
evaluated, it was seen that 73 (92.4%) had RP, 63 (79.7%) sclerodactyly, 14
(17.7%) digital ulcer and 22 (27.8%) telangiectasia. Eight (10.1%) patients had
articular complaints. Antinuclear antibody (ANA) was (+) in 49 (62%) of the
patients and anti-Scl-70 was (+) in 31 (39.2%). 74 patients (93.7%) were still
alive and 5 (6.3%) died. No disease-related factor was found to be effective on
mortality (p> 0.05). Malignancy was developed in 4 (5.1%) patients. Only
high resolution computed chest tomography (HRCT) shot count were found to be an
effective factor for cancer development (OR 1.74, p = 0.023 (CI 1.081-2.829).
In conclusion, causes of mortality and malignancy were similar with the
literature in patients we followed up with SSc. We found a correlation between
the incidence of chest CT and the malignancy development unlike the literature.
This result should be supported by studies involving larger patient numbers. </span> <span lang="en-us" style="font-size:9pt;color:#222222;" xml:lang="en-us"> </span> </p> <p> </p> <p class="MsoNormal" style="text-align:justify;line-height:normal;"> <span lang="en-us" style="font-size:10pt;font-family:’Times New Roman’, serif;" xml:lang="en-us">   </span> </p> <p> </p> <p> </p>}, number={3}, publisher={Eskişehir Osmangazi Üniversitesi}